AR085483A1 - Tratamiento de enfermedad de deficit de atencion con hiperactividad, metodo de tratamiento, combinacion farmaceutica - Google Patents

Tratamiento de enfermedad de deficit de atencion con hiperactividad, metodo de tratamiento, combinacion farmaceutica

Info

Publication number
AR085483A1
AR085483A1 ARP120100944A ARP120100944A AR085483A1 AR 085483 A1 AR085483 A1 AR 085483A1 AR P120100944 A ARP120100944 A AR P120100944A AR P120100944 A ARP120100944 A AR P120100944A AR 085483 A1 AR085483 A1 AR 085483A1
Authority
AR
Argentina
Prior art keywords
treatment
hyperactivity
azabicyclo
benzofuran
pyridinyl
Prior art date
Application number
ARP120100944A
Other languages
English (en)
Inventor
Merouane Bencherif
Terry Hauser
Geoffrey Charles Dunbar
David A Hosford
Gregory J Gatto
Kristen Jordan
Anthony Carl Segreti
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of AR085483A1 publication Critical patent/AR085483A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Abstract

Reivindicación 1: Un método de tratamiento de TDAH, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella.Reivindicación 16: Una combinación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella, u otro agonista de a7, con uno o más agentes estimulantes, uno o más agentes antidepresivos y uno o más agentes antihipertensivos para tratar el TDAH del tipo combinado, desatento o hiperactivo/impulsivo. Reivindicación 17: Una combinación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2loct-3-il)benzofuran-2-carboxamida o una sal farmacéuticamente aceptable de ella con otro agente terapéutico para tratar el TDAH.
ARP120100944A 2011-03-23 2012-03-22 Tratamiento de enfermedad de deficit de atencion con hiperactividad, metodo de tratamiento, combinacion farmaceutica AR085483A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466644P 2011-03-23 2011-03-23
US201161489740P 2011-05-25 2011-05-25
US201161510092P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
AR085483A1 true AR085483A1 (es) 2013-10-02

Family

ID=45922840

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100944A AR085483A1 (es) 2011-03-23 2012-03-22 Tratamiento de enfermedad de deficit de atencion con hiperactividad, metodo de tratamiento, combinacion farmaceutica

Country Status (3)

Country Link
AR (1) AR085483A1 (es)
TW (1) TW201244717A (es)
WO (1) WO2012129262A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه

Also Published As

Publication number Publication date
WO2012129262A1 (en) 2012-09-27
TW201244717A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
BR112015006828A2 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015006341A2 (pt) compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
IN2015DN00376A (es)
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112012007829A2 (pt) método para tratar bexiga hiperativa, e, composição farmacêutica.
MX2021002321A (es) Nuevos metodos.
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
ATE543492T1 (de) Behandlung von lungenkrebs
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
BR112014010729A2 (pt) métodos para tratamento de ataques de gota

Legal Events

Date Code Title Description
FA Abandonment or withdrawal